» Articles » PMID: 34816053

Protocol for the DeFOG Trial: A Randomized Controlled Trial on the Effects of Smartphone-based, On-demand Cueing for Freezing of Gait in Parkinson's Disease

Overview
Date 2021 Nov 24
PMID 34816053
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Freezing of gait (FOG) is a highly incapacitating symptom that affects many people with Parkinson's disease (PD). Cueing triggered upon real-time FOG detection (on-demand cueing) shows promise for FOG treatment. Yet, the feasibility of implementation and efficacy in daily life is still unknown. Therefore, this study aims to investigate the effectiveness of DeFOG: a smartphone and sensor-based on-demand cueing solution for FOG.

Methods: Sixty-two PD patients with FOG will be recruited for this single-blind, multi-center, randomized controlled phase II trial. Patients will be randomized into either the intervention group or the active control group. For four weeks, both groups will receive feedback about their physical activity using the wearable DeFOG system in daily life. In addition, the intervention group will also receive on-demand auditory cueing and instructions. Before and after the intervention, home-based assessments will be performed to evaluate the primary outcome, i.e., "percentage time frozen" during a FOG-provoking protocol. Secondary outcomes include the training effects on physical activity monitored over 7 days and the user-friendliness of the technology.

Discussion: The DeFOG trial will investigate the effectiveness of personalized on-demand cueing in a controlled design, delivered for 4 weeks in the patient's home environment. We anticipate that DeFOG will reduce FOG to a greater degree than in the control group and we will explore the impact of the intervention on physical activity levels. We expect to gain in-depth insight into whether and how patients control FOG using cueing methods in their daily lives.

Trial Registration: Clinicaltrials.gov NCT03978507.

Citing Articles

Evaluating gait and postural responses to subthalamic stimulation and levodopa: A prospective study using wearable technology.

Cani I, DAscanio I, Baldelli L, Lopane G, Ranciati S, Mantovani P Eur J Neurol. 2024; 32(1):e16580.

PMID: 39702816 PMC: 11658965. DOI: 10.1111/ene.16580.


Which Gait Tasks Produce Reliable Outcome Measures of Freezing of Gait in Parkinson's Disease?.

Zoetewei D, Ginis P, Goris M, Gilat M, Herman T, Brozgol M J Parkinsons Dis. 2024; 14(6):1163-1174.

PMID: 39121137 PMC: 11380302. DOI: 10.3233/JPD-240134.


Insights into Parkinson's Disease-Related Freezing of Gait Detection and Prediction Approaches: A Meta Analysis.

Elbatanouny H, Kleanthous N, Dahrouj H, Alusi S, Almajali E, Mahmoud S Sensors (Basel). 2024; 24(12).

PMID: 38931743 PMC: 11207947. DOI: 10.3390/s24123959.


Investigating gait-responsive somatosensory cueing from a wearable device to improve walking in Parkinson's disease.

Li D, Hallack A, Gwilym S, Li D, Hu M, Cantley J Biomed Eng Online. 2023; 22(1):108.

PMID: 37974260 PMC: 10652624. DOI: 10.1186/s12938-023-01167-y.


IoT-Enabled Gait Assessment: The Next Step for Habitual Monitoring.

Young F, Mason R, Morris R, Stuart S, Godfrey A Sensors (Basel). 2023; 23(8).

PMID: 37112441 PMC: 10144082. DOI: 10.3390/s23084100.


References
1.
Lord S, Bindels H, Ketheeswaran M, Brodie M, Lawrence A, Close J . Freezing of Gait in People with Parkinson's Disease: Nature, Occurrence, and Risk Factors. J Parkinsons Dis. 2020; 10(2):631-640. DOI: 10.3233/JPD-191813. View

2.
Ehgoetz Martens K, Peterson D, Almeida Q, Lewis S, Hausdorff J, Nieuwboer A . Behavioural manifestations and associated non-motor features of freezing of gait: A narrative review and theoretical framework. Neurosci Biobehav Rev. 2020; 116:350-364. DOI: 10.1016/j.neubiorev.2020.06.026. View

3.
Gilat M . How to Annotate Freezing of Gait from Video: A Standardized Method Using Open-Source Software. J Parkinsons Dis. 2019; 9(4):821-824. DOI: 10.3233/JPD-191700. View

4.
Hughes A, Daniel S, Kilford L, Lees A . Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992; 55(3):181-4. PMC: 1014720. DOI: 10.1136/jnnp.55.3.181. View

5.
Nasreddine Z, Phillips N, Bedirian V, Charbonneau S, Whitehead V, Collin I . The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005; 53(4):695-9. DOI: 10.1111/j.1532-5415.2005.53221.x. View